


# Quantitative analysis of small molecules in biological samples

Jeevan Prasain, Ph.D.

Department of Pharmacology &  
Toxicology, UAB




## Class Overview

- Introduction to LC-MS/MS analysis
- Quantitative analysis of puerarin, and phytoestrogens in biological samples by LC-MS/MS

## Why quantification of drug/drug metabolites in plasma/tissues PK studies is so important?

- An accurate and fast analytical method for measuring the concentrations of a compound in plasma or tissue is the first step in order to yield the PK of a compound
- Established assay for human sample analyses (plasma, serum or urine matrix) needs to be more rugged, robust and be able to withstand the test of time during this the longest phase of clinical development. The requirements and adherence to specificity, selectivity and stability will become very important


## Bio-analytical works



## Challenges in bioanalytical works

- Low concentrations of metabolites in a complex matrix
- Number of samples (eg.10-1000)/study
- Wide dynamic concentration range (pico to microgram/mL)

**Sample preparation is a crucial step in removing the interfering compounds from biological matrix**



***The method of choice will be determined by the sample matrix and the concentration of compounds In samples***

## **Choice of Good Internal Standards**

- **A stable isotopically labeled IS is preferable.**
- **Is not found in the original sample**
- **In the absence of stable isotopically labeled internal std, the structure of the internal standard needs to be similar to the analyte and co-elute with the analyte.**
- **Should not react chemically with the analyte.**

## **Problems encountered in LC-MS analysis** **Matrix effect on Ion suppression?**

- **The presence of endogenous substances from matrix, i.e., organic or inorganic molecules present in the sample and that are retained in the final extract**
- **Exogenous substances, i.e., molecules not present in the sample but coming from various external sources during the sample preparation**

## LC-MS analysis

### HPLC


- Isocratic
- Gradient
- Reversed-nonpolar stationary, polar mobile
- Normal- polar stationary, nonpolar mobile
- HILIC- hydrophilic interaction

*Common column- 100-200 mm long and 3-4.6 mm diameter  
Smaller diameter offers better separation and sensitivity*


## Choice of solvent

- Common organic solvents- Methanol and acetonitrile, water alone is poor solvent for ESI
- Acetonitrile vs methanol- acetonitrile (expensive), water/methanol creates more pressure than water/acetonitrile
- Elution strength- usually acetonitrile > methanol
- Methanol provide a more stable spray and better sensitivity than acetonitrile in negative ion mode.

## Severe ion suppression effect for codeine and glafenin was observed with PPT and SPE-PPT



## APCI is less prone than ESI to the effects of ion suppression



King et al. *J. Am Soc Mass Spectrom* 2000

## Eliminating matrix effects


1. Preparing more cleaner samples.
2. Concentrating analyte of interest
3. Improve analytical system performance

### % matrix effects

$$= \frac{[\text{Response post-extracted spiked sample}] - 1}{\text{response non-extracted neat samples}} \times 100$$

## Carry over a big problem?

Previously injected sample which appears upon subsequent analyses due to physico-chemical property of the sample, analysis system or both.



## **Analytical method validation**

- **Should demonstrate specificity, linearity, recovery, accuracy, precision**
- **Lower limit of quantification**
- **Stability (freeze/thaw)**
- **Robustness & ruggedness**
- **Matrix effects**

## **Method validation..**


- **Specificity is established by the lack of interference peaks at the retention time for the internal standard and the analyte.**
- **Accuracy is determined by comparing the calculated concentration using calibration curves to known concentration. The LLQ is defined as the smallest amount of the analyte that could be measured in a sample with sufficient precision (%CV) and accuracy (within 20% for both parameters) and is chosen as the lowest concentration on the calibration curve.**



# Linearity

- It indicates the relationship between changed concentrations and proportional response
- $R^2 > 0.95$ , with at least 5 concentration levels

**Standard curve non-linearity is possible due to detector saturation, dimer/multimer formation, and or ESI droplet saturation at higher concentration**



Source: Bakhtiar & Majumdar.  
Journal of Pharmacological and Toxicological Methods, 2007

## **Precision..**

- The closeness of agreement between a series of measurements obtained from multiple samples of the homogenous sample.- Repeatability
- %CV

## **Robustness**

- Ability to remain unaffected by small but deliberate variations in the LC-MS/MS method parameters- such as pH in a mobile phase, composition of solvents, different lots of column, flow rates etc.

## Ruggedness

- Indicates degree of reproducibility of test results under a variety of conditions such as different labs, instruments and reagents etc.

## Recovery

- Recovery is a ratio of the detector response of an analyte from an extracted sample to the detector response of the analyte in post extracted sample (spiked sample)
- $\%RE = \frac{\text{response extracted sample}}{\text{response post extracted spiked sample}} \times 100$

## LC/MS/MS Method for Puerarin

**Column:** Waters X-Terra C18 with guard,  
2.1 x 100 mm, 3.5 micron

**Mobile Phase A:** 10% MeCN + 10 mM NH<sub>4</sub>OAc

**Mobile Phase B:** 70% MeCN + 10mM NH<sub>4</sub>OAc

**Gradient:** 0 minutes = 100% A

6 minutes = 100% B

7 minutes = 100% A

10 minutes = Stop

**Injection Volume:** 20 ul

**Flow Rate:** 0.2 ml/min split flow

**Mass Spectrometer:** Negative Electrospray

**Mass Transitions:** 415/267 (Puerarin)

415/295 (Puerarin)

269/149 (apigenin, IS)

Table 1.  
Summary of calibration curves (n =5)

Concentration (ng/ml)	Mean $\pm$ S.D.	CV (%)	Accuracy (%)
2.0	2.21 $\pm$ 0.16	7.00	110.7
5.0	5.22 $\pm$ 0.28	5.30	104.48
50	45.32 $\pm$ 2.53	5.60	90.64
500	473.60 $\pm$ 26.57	5.60	94.72
1000	1021.20 $\pm$ 71.53	7.00	102.12
5000	5340 $\pm$ 420.18	7.90	106.80


Mean r = 0.996

Table 2.


Assay validation characteristics of the method for the determination of puerarin in rat serum (n =5)

Concentration (ng/ml)	Mean $\pm$ S.D.	CV (%)	Accuracy (%)
2.0	2.21 $\pm$ 0.16	7.00	110.7
4.0	3.96 $\pm$ 0.30	7.90	99.20
8.32	7.32 $\pm$ 1.00	14.40	113.30
20	19.20 $\pm$ 1.20	6.30	96.00
200	203.20 $\pm$ 19.41	9.60	101.60
832	821.18 $\pm$ 55.86	6.80	101.31
2000	2240 $\pm$ 96.70	4.30	112.00

### Ion chromatograms of a rat serum spiked sample (0.01 $\mu$ M of puerarin) vs. blank serum



**Average serum concentration of puerarin versus time after Oral administration of 50 mg/kg puerarin**



**MRM chromatogram showing separation of 11 phytoestrogens using a 2 min run time**





Table 1. MS/MS parameters optimized for phytoestrogens and internal standards

Analyte	Q1/Q3	Dwell (msec)	DP (V)	CE (eV)	CXP (V)
Equol	314/119	50	-65	-30	-5
Daidzein	253/132	50	-65	-55	-10
Dihydrodaizein	255/149	50	-50	-30	-9
O-DMA	257/108	50	-70	-40	-5
Genistein	269/133	50	-75	-40	-5
Glycitein	283/184	50	-65	-45	-5
Formononetin	267/251	50	-75	-35	-5
Coumestrol	267/91	50	-50	-50	-2
Biochanin A	283/268	50	-70	-30	-5
Enterolactone	297/253	50	-80	-30	-10
Enterodiol	301/253	50	-70	-30	-9
Phenophthalein	317/93	50	-50	-20	-5
4-MU	175/119	50	-50	-38	-4
Chrysin	253/143	50	-50	-50	-5

DP = Declustering potential  
 CE = Collision energy  
 CXP = Cell exit potential

Prasain et al., 2010

## Specificity of the assay - no peaks from matrix



## Calibration range and lower limit of Quantification (LLOQ) of analytes

Analyte	Calibration range (ng/ml)	LLOQ (ng/ml)
Equol	1 - 5,000	1
Daidzein	2 - 5,000	2
DHD	2 - 5,000	2
O-DMA	1 - 5,000	1
genistein	2 - 5,000	2
Glycitein	5 - 5,000	5
Formononetin	1 - 5,000	1
Coumestrol	1 - 5,000	1
Bichanin-A	1 - 5,000	1
6-OH-ODMA	20 - 5,000	20
Enterodiol	2 - 5,000	2
Enterolactone	1 - 5,000	1

## Precision and accuracy of quality control samples

Analyte	Nominal concentration (ng/mL)	Accuracy (%)			Precision (%CV)			Inter-day
		Day 1	Day 2	Day 3	Day 1	Day 2	Day 3	
Equol	50	100.42	90.13	96.60	2.01	4.33	5.11	3.74
	500	103.30	99.85	114.66	2.31	5.61	1.93	2.97
	2000	97.60	89.90	103.96	6.11	10.61	10.13	8.34
Daidzein	50	99.98	102.73	94.04	4.35	6.44	8.23	6.62
	500	101.48	98.31	97.73	3.14	5.44	7.42	5.38
	2000	92.50	87.41	86.03	2.88	3.61	3.96	3.58
Dihydrodaidzein	50	103.00	100.15	101.66	3.94	1.43	4.99	3.63
	500	103.79	95.20	106.00	3.96	6.44	3.35	4.34
	2000	91.70	90.40	96.33	1.68	5.80	6.60	2.82
O-DMA	50	104.00	93.72	96.51	5.16	4.71	5.80	5.32
	500	105.67	93.78	102.33	3.22	9.42	5.54	5.84
	2000	101.20	93.57	100.93	5.53	5.37	6.53	3.63
Genistein	50	107.66	106.83	99.08	3.97	3.37	6.65	4.86
	500	97.50	88.90	91.36	5.40	3.61	5.60	4.96
	2000	95.13	92.28	93.38	2.63	3.97	4.17	3.59

### Comparison of precision intra-day and inter-day



Table 5. Stability of quality control samples

Compound	Nominal Concentration (ng/mL)	Mean measured concentration (ng/mL)	
		autosampler at 4 °C, 72h	long storage -20 °C, 2 months
Equol	50	43.35 ± 2.50	45.68 ± 3.98
	500	487.80 ± 9.20	475.66 ± 30.16
	2000	1793.33 ± 67.42	1921.66 ± 94.74
Daidzein	50	47.03 ± 2.50	50.83 ± 1.87
	500	534.20 ± 21.05	491.66 ± 7.17
	2000	1848.33 ± 72.77	1861.66 ± 71.67
Dihydrodaidzein	50	45.55 ± 1.97	47.52 ± 5.23
	500	485.83 ± 26.35	219.20 ± 15.90
	2000	1738.33 ± 85.18	828.50 ± 27.01
O-DMA	50	48.31 ± 3.75	54.80 ± 5.67
	500	469.16 ± 24.01	534.66 ± 28.57
	2000	1861.66 ± 114.61	2151.66 ± 110.89
Genistein	50	50.90 ± 3.19	51.16 ± 3.34
	500	487.33 ± 33.15	497.33 ± 37.59
	2000	1875.00 ± 116.40	2190.00 ± 11.83
Glycitein	50	44.31 ± 2.44	40.15 ± 1.98
	500	481.00 ± 39.11	489.50 ± 28.26
	2000	1886.66 ± 87.10	2045.00 ± 191.91
Formononetin	50	47.36 ± 4.16	47.58 ± 3.22
	500	512.33 ± 26.41	507.66 ± 27.82
	2000	2018.33 ± 106.09	1925.00 ± 167.06
Coumestrol	50	46.26 ± 6.68	56.80 ± 2.37
	500	549.33 ± 36.74	498.00 ± 26.1
	2000	2120.00 ± 104.30	1905.00 ± 128.17
Biochanin A	50	52.47 ± 2.27	56.10 ± 1.49
	500	444.00 ± 29.81	523.00 ± 23.34
	2000	1893.33 ± 202.06	2130.00 ± 88.31
Enterodiol	50	44.96 ± 3.45	46.84 ± 2.47
	500	488.16 ± 13.04	489.83 ± 20.79
	2000	1906.66 ± 68.89	1963.33 ± 119.27

Mean recovery (%) of phytoestrogens following extraction

Conc. (ng/mL)	Equol	Dz	DHD	O-DMA	GN	Gly	Form	Cm	Bio	6-OH-ODMA	Ent	End
5	91.04	87.57	98.95	72.79		94.49	87.36		84.10		78.62	73.60
50	76.58	80.09	80.88	71.00		74.96	82.08	76.63	74.26		75.17	73.82
500	85.70	86.49	89.39	71.70		91.18	80.15	86.97	54.84		92.50	92.78
5000	87.32	79.57	95.02	81.97		92.45	93.22	81.52	67.67		92.30	77.70

Dz = daidzein, DHD = dihydrodaidzein, GN = genistein, Gly = glycitein, Form = formononetin, Bio = biochanin A, Ent = enterolactone  
End = enterodiol

## Conclusions

- The sensitive & accurate analysis of biological samples remains a significant challenge.
- Although SPE and PPT can be HTS, LLE where extensive clean up is required, is less prone to matrix effects.
- Column temperature, LC column particles, gradient and run time can influence chromatographic separation.
- Method of validation is always performed with spiked matrix same as the biological sample following the validation criteria.